SavedAdd your journal

Journals / Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi / 2026 / Volume: 46 Issue: 3

A Simple and Reproducible Melatonin Syrup Formulation for Personalized Pediatric Therapies

Merve Nenni(CUKUROVA UNIVERSITY, FACULTY OF PHARMACY)0000-0003-3165-1060
İzgi Bayraktar Alkan(HACETTEPE UNIVERSITY, FACULTY OF PHARMACY)0000-0002-2694-4072
Esra Demirtürk(CUKUROVA UNIVERSITY, FACULTY OF PHARMACY, PHARMACY PR.)0000-0002-8918-0073
Mustafa Sinan Kaynak(ANADOLU UNIVERSITY, VOCATIONAL SCHOOL)0000-0003-2917-2407
Kutay Demirkan(HACETTEPE UNIVERSITY, FACULTY OF PHARMACY)0000-0002-6427-5826
Mustafa Çelebier(HACETTEPE UNIVERSITY, FACULTY OF PHARMACY)0000-0001-7712-5512
Pages
—
Publication Date
2026-09-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The syrup can be easily prepared using commercially available melatonin tablets in hospital pharmacies or home settings, using safe pediatric excipients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Sleep disorders in children can negatively impact their development and quality of life.
📊
Key Findings & Data:Each teaspoon contains 1.0 mg of melatonin, allowing for flexible and precise dosing customized to individual patient needs.
💡
Conclusion & Impact:The syrup can be easily prepared using commercially available melatonin tablets in hospital pharmacies or home settings, using safe pediatric excipients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Melatonin · Pediatric Sleep Disorders · Personalized Medicine

Abstract

Sleep disorders in children can negatively impact their development and quality of life. While melatonin is commonly used to manage these issues, there are no FDA-approved formulations specifically designed for children, and traditional tablet forms can be challenging for these patients. This study aims to develop a patient-friendly melatonin syrup formulation suitable for personalized pediatric therapies. Each teaspoon contains 1.0 mg of melatonin, allowing for flexible and precise dosing customized to individual patient needs. Melatonin content was quantified using a reversed-phase HPLC method with UV/Visible detector (HPLC-UV/Vis) ifadesi ‘with UV/Visible detector (HPLC-UV/Vis) that was developed and validated in line with ICH Q2(R1), demonstrating selectivity, linearity (1.0–30.0 μg/mL; R²=0.999), and intra- and inter-day accuracy and precision within 2%. Stability studies demonstrated that the syrup remains stable and retains its potency for at least seven days at room temperature. This syrup formulation enhances palatability and ease of administration, potentially improving therapeutic outcomes in children with sleep disorders through personalized treatment approaches. The syrup can be easily prepared using commercially available melatonin tablets in hospital pharmacies or home settings, using safe pediatric excipients.

🔖

Cite This Article

Nenni, M., Alkan, İ. B., Demirtürk, E., Kaynak, M. S., Demirkan, K., Çelebier, M. (2026). A Simple and Reproducible Melatonin Syrup Formulation for Personalized Pediatric Therapies. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, Volume: 46 Issue: 3. https://doi.org/10.52794/hujpharm.2012089

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (22)

  1. Sánchez-Barceló EJ, Mediavilla MD, Reiter RJ. Clinical uses of melatonin in pediatrics. Int J Pediatr. 2011;2011(1):1-9. https://doi.org/10.1155/2011/892624
  2. Glass A, Attrill C, Magee C, Blunden S. Factors associated with melatonin use in child sleep disturbance: A survey of Australian parents. Sleep Med. 2023;107:330-7. https://doi.org/10.1016/j.sleep.2023.04.026.
  3. Lajoinie A, Janiaud P, Henin E, Gleize J-C, Berlion C, Nguyen KA, et al. Assessing the effects of solid versus liquid dosage forms of oral medications on adherence and acceptability in children. The Cochrane Database of Syst Rev. 2017;2017(9). https://doi.org/10.1002/14651858.Cd012783.
  4. Abdülbaki A, Per H. Otizm Spektrum Bozukluğu ve Dikkat Eksikliği ve Hiperaktivite Bozukluğu Olan Çocuklarda Uyku Sağlığı ve Bozuklukları. In: Per H, Arhan E, editors. Çocuklarda Uyku Sağlığı ve Bozuklukları. Ankara: Türkiye Klinikleri; 2020. p. 81-6.
  5. Venables R, Batchelor H, Hodson J, Stirling H, Marriott J. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population. Int J Pharm. 2015;480(1-2):55-62. https://doi.org/10.1016/j.ijpharm.2015.01.023
  6. Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case? Control study of inpatients in a pediatric hospital. BMC Medicine. 2013;11(1):1-8.
  7. Validation Of Analytical Procedures: Text And Methodology Q2(R1): The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2005 [cited 2026 May]. Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf.
  8. Stability Testing Of New Drug Substances And Products Q1A(R2): The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2003 [cited 2026 May]. Available from: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
  9. Rowe RC, Sheskey P, Quinn M. Handbook of pharmaceutical excipients: Libros Digitales-Pharmaceutical Press; 2009.
  10. van Riet-Nales DA, Schobben AF, Vromans H, Egberts TC, Rademaker CM. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects. Arch Dis Child. 2016;101(7):662-9. https://doi.org/10.1136/archdischild-2015-308227
  11. USP General Chapter 795: Pharmaceutical Compounding – Nonsterile Preparations. United States Pharmacopeia and National Formulary (USP-NF). Rockville, MD. [cited 2026 May]. Available from: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/gc795.pdf.
  12. Melatonin 1 mg/ml oral solution. Patient Information Leaflet (PIL). Electronic Medicines Compendium (emc). [cited 2026 May]. Available from: https://www.medicines.org.uk/emc/product/10419/pil.13.
  13. Voquily 1 mg/ml oral solution. Summary of Product Characteristics (SmPC). Health Products Regulatory Authority (HPRA). [cited 2026 May]. Available from: https://assets.hpra.ie/products/Human/37987/Licence_PA22701-002-001_13032024160052.pdf.
  14. Filali S, Bergamelli C, Lamine Tall M, Salmon D, Laleye D, Dhelens C, et al. Formulation, stability testing, and analytical characterization of melatonin-based preparation for clinical trial. J Pharm Anal. 2017;7(4):237-243. http://doi.org/10.1016/j.jpha.2017.04.001.
  15. Friciu M, Savji T, Zaraa S, Leclair G. Evaluation of stability of melatonin in extemporaneously compounded oral suspensions. J Pharm Pract and Res. 2016;46(1):28-33. https://doi.org/10.1002/jppr.1171.
  16. Schroder CM, Malow BA, Maras A, Melmed RD, Findling RL, Breddy J, et al. Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver’s Quality of Life. J Autism Dev Disord. 2019;49(8):3218-3230. http://doi.org/10.1007/s10803-019-04046-5.
  17. Pranil T, Moongngarm A, Loypimai P. Influence of pH, temperature, and light on the stability of melatonin in aqueous solutions and fruit juices. Heliyon. 2020;24;6(3):e03648. http://doi.org/10.1016/j.heliyon.2020.e03648.
  18. Jadhav S. ICH Q14 Inspired-QBD Mediated Development And Validation Of Innovative Stability-Indicating HPLC Method For Estimating Melatonin From Sleep-Enhancing Tablet Formulation. Afr J Biomed Res. 2024;6755-6765. https://doi.org/10.53555/AJBR.v27i4S.4867
  19. Xu XR, Li XY, Li XZ, Li HB. Degradation of melatonin by UV, UV/H2O2, Fe2+/H2O2 and UV/Fe2+/H2O2 processes. Sep Purif Technol. 2009;68(2):261-266. https://doi.org/10.1016/j.seppur.2009.05.013.
  20. Jacobson JL, Tylka J, Glazer S, Zhang Y, Cosme R, Silvestri JM, Patwari PP. Melatonin Use in Pediatric Intensive Care Units: A Single-Center Experience. Med Sci (Basel, Switzerland). 2023;28;11(3):55. http://doi.org/10.3390/medsci11030055.
  21. Sadeh H, Meiri G, Zigdon D, Ilan M, Faroy M, Michaelovski A, Sadaka Y, Dinstein I, Menashe I. Adherence to treatment and parents’ perspective about effectiveness of melatonin in children with autism spectrum disorder and sleep disturbances. Child Adolesc Psychiatry Ment Health. 2023; 27;17(1):123. http://doi.org/10.1186/s13034-023-00669-w.
  22. Arslan Azizoğlu G, Azizoğlu E, Tuncay Tanrıverdi S, Özer Ö. A validated HPLC method for simultaneous estimation of melatonin and octyl methoxycinnamate in combined pharmaceutical applications. Marmara Pharm J. 2017;21(4):921-930. http://doi.org/10.12991/mpj.2017.16.